Novartis’s Tabrecta Earns NMPA Nod for MET-Positive Advanced NSCLC in China
Swiss pharmaceutical titan Novartis has secured marketing approval from China’s National Medical Products Administration (NMPA)...
Drug
Biosion’s Bosakitug Shows Positive Results in Atopic Dermatitis Phase II POC Study
Biosion, a clinical-stage biotechnology company with operations in Delaware, U.S., and China, has announced key...
Ascletis Pharma’s ASC41 Shows Promise in Phase II Study for Metabolic Dysfunction-Associated Steatohepatitis
Ascletis Pharma Inc. (HKG: 1672), a biopharmaceutical company based in China, has announced positive interim...
Shanghai Pharmaceuticals Halts Development of B001 and I022 for Selected Indications
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced the discontinuation of clinical studies and...
Brii Biosciences’ BRII-179 Shows Promise in Phase II Trials for Chronic Hepatitis B at EASL 2024
Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has presented new...
AI-Powered Biotech Insilico Medicine Initiates Phase I Clinical Trial for Inflammatory Bowel Disease Drug
Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has...
Jiangxi Fushine’s Subsidiary LinkChem Eyes Hong Kong IPO Amid Strong Revenue Growth
Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE: 300497), a Chinese pharmaceutical company, has announced that its...
Gilead’s Bulevirtide-PegIFN Combo Achieves High HDV Remission Rates in Phase IIb Trial
Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company at the forefront of HIV and liver...
AbbVie’s Telisotuzumab Vedotin Earns Breakthrough Therapy Designation in China for c-Met Positive NSCLC
AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced that...
Qilu Pharmaceutical’s Generic Pomalidomide Wins NMPA Nod for Multiple Myeloma Treatment
Qilu Pharmaceutical, a leading pharmaceutical company based in China, has received approval from the National...
Fosun Pharma’s FCN-159 Receives Priority Review Status from NMPA for Pediatric Neurofibromatosis
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...
Luye Pharma Submits Market Approval Application for Rivastigmine Patch in Japan
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...
HutchMed Initiates Phase I Clinical Trial for HMPL-506 in Hematologic Malignancies
HutchMed (HKG: 0013, NASDAQ: HCM) has announced the commencement of a Phase I clinical study...
Sino Biopharmaceutical Presents FS222 Phase I Results at ASCO Annual Meeting
Sino Biopharmaceutical Ltd (HKG: 1177), a prominent biopharmaceutical company in China, has presented updates from...
Jiangsu Hengrui’s HER2 Targeted ADC SHR-A1811 Poised to Earn Breakthrough Designation in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
J&J’s Tecvayli Shows Promising Response Rates in Multiple Myeloma Trial
Johnson & Johnson (J&J; NYSE: JNJ) has reported updates from a Phase I/II clinical trial...
Bristol Myers Squibb’s Breyanzi Shows Promising Results in Three Lymphoma Trials
Bristol Myers Squibb (BMS; NYSE: BMY) has announced results from three distinct clinical trials assessing...
AbelZeta and AstraZeneca’s C-CAR031 Shows Promising Results in HCC Treatment
AbelZeta, a Sino-US biotech company with operations in Rockville, Maryland, and Shanghai, has presented data...
InnoCare’s Tafasitamab-Lenalidomide Combo on Track for Priority Review in China for DLBCL Treatment
The Center for Drug Evaluation (CDE) website has indicated that InnoCare (HKG: 9969; SHA: 688428),...
Jiangsu Hengrui Receives NMPA Approval to Begin Clinical Trials for New Anticancer Biologic
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...